607 related articles for article (PubMed ID: 27004558)
1. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus.
Gaál K; Tarr T; Lőrincz H; Borbás V; Seres I; Harangi M; Fülöp P; Paragh G
Lipids Health Dis; 2016 Mar; 15():60. PubMed ID: 27004558
[TBL] [Abstract][Full Text] [Related]
2. Altered lipid subfraction profile and impaired antioxidant defense of high-density lipoprotein in Smith-Lemli-Opitz syndrome.
Lőrincz H; Harangi M; Oláh AV; Szabó GP; Fülöp P; Somodi S; Paragh G; Seres I
Pediatr Res; 2015 May; 77(5):703-9. PubMed ID: 25668223
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.
Delgado Alves J; Ames PR; Donohue S; Stanyer L; Nourooz-Zadeh J; Ravirajan C; Isenberg DA
Arthritis Rheum; 2002 Oct; 46(10):2686-94. PubMed ID: 12384928
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T
Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes.
Viktorinova A; Jurkovicova I; Fabryova L; Kinova S; Koren M; Stecova A; Svitekova K
Diabetes Res Clin Pract; 2018 Jun; 140():174-182. PubMed ID: 29626583
[TBL] [Abstract][Full Text] [Related]
6. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.
Kiss E; Seres I; Tarr T; Kocsis Z; Szegedi G; Paragh G
Ann N Y Acad Sci; 2007 Jun; 1108():83-91. PubMed ID: 17893973
[TBL] [Abstract][Full Text] [Related]
7. Relationship between selected oxidative stress markers and lipid risk factors for cardiovascular disease in middle-aged adults and its possible clinical relevance.
Viktorinova A; Svitekova K; Stecova A; Krizko M
Clin Biochem; 2016 Aug; 49(12):868-72. PubMed ID: 27240017
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus.
López P; Rodríguez-Carrio J; Martínez-Zapico A; Pérez-Álvarez ÁI; López-Mejías R; Benavente L; Mozo L; Caminal-Montero L; González-Gay MA; Suárez A
Thromb Haemost; 2017 Nov; 117(11):2194-2206. PubMed ID: 29044294
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of paraoxonase activity and lipid profile in lupus patients].
Kiss E; Seres I; Zsolt K; Tarr T; Csípo I; Szegedi G; Paragh G
Orv Hetil; 2005 Nov; 146(47):2395-402. PubMed ID: 16398152
[TBL] [Abstract][Full Text] [Related]
10. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
Moradi H; Pahl MV; Elahimehr R; Vaziri ND
Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
[TBL] [Abstract][Full Text] [Related]
11. Association of serum amyloid A and oxidative stress with paraoxonase 1 in sarcoidosis patients.
Ivanišević J; Kotur-Stevuljević J; Stefanović A; Spasić S; Vučinić Mihailović V; Videnović Ivanov J; Jelić-Ivanović Z
Eur J Clin Invest; 2016 May; 46(5):418-24. PubMed ID: 26919159
[TBL] [Abstract][Full Text] [Related]
12. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
[TBL] [Abstract][Full Text] [Related]
13. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
[TBL] [Abstract][Full Text] [Related]
15. High density lipoprotein subfractions and paraoxonase 1 in children.
Muchová J; Andrezálová L; Oravec S; Nagyová Z; Garaiova I; Ďuračková Z
Acta Biochim Pol; 2016; 63(3):555-63. PubMed ID: 27262841
[TBL] [Abstract][Full Text] [Related]
16. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
Rosenblat M; Karry R; Aviram M
Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
[TBL] [Abstract][Full Text] [Related]
17. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus.
Batuca JR; Ames PR; Isenberg DA; Alves JD
Ann N Y Acad Sci; 2007 Jun; 1108():137-46. PubMed ID: 17893980
[TBL] [Abstract][Full Text] [Related]
18. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus.
Batuca JR; Ames PR; Amaral M; Favas C; Isenberg DA; Delgado Alves J
Rheumatology (Oxford); 2009 Jan; 48(1):26-31. PubMed ID: 19000993
[TBL] [Abstract][Full Text] [Related]
19. Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity.
Kjellmo CA; Karlsson H; Nestvold TK; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Lappegård KT; Hovland A
J Clin Lipidol; 2018; 12(1):193-202. PubMed ID: 29146227
[TBL] [Abstract][Full Text] [Related]
20. Paraoxonase 1 activity and level of antibodies directed against oxidized low density lipoproteins in a group of an elderly population in Poland - PolSenior study.
Bednarska-Makaruk M; Rodo M; Szirkowiec W; Mossakowska M; Puzianowska-Kuźnicka M; Skalska A; Zdrojewski T; Ryglewicz D; Wehr H
Arch Gerontol Geriatr; 2015; 60(1):153-61. PubMed ID: 25459919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
